BASKING RIDGE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the ...
Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong ...
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy ...
Caladrius reported in May 2020 the compelling positive results of its ESCaPE-CMD Phase 2a study of CLBS16 for the treatment of coronary microvascular dysfunction (“CMD”), a disease that continues to ...
Not an acquisition but a “merger of equals.” That’s how Caladrius Biosciences and Cend Therapeutics have described their transformation into the newly christened Lisata Therapeutics. The all-stock ...
Caladrius Biosciences Inc., a clinical-stage biopharmaceutical company based in Basking Ridge, has been on the hunt for “strategic development opportunities” this past year, according to President and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results